Oncternal therapeutics, inc. (ONCT)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash flows from operating activities
Net loss

-34,188

-38,418

-30,439

-17,724

-18,703

-

-

-

-

-

-

Net income (loss)

-

-

-

-

-

-39,411

-42,111

-27,075

-33,294

15,294

-46,256

Adjustments to reconcile net loss to net cash used in operating activities:
In-process research and development

18,088

-

-

-

-

-

-

-

-

-

-

Private placement expenses recorded as other income (expense), net

-

-

-

-

-

297

-

-

-

-

-

Gain on sale of FARESTON

-

-

-

-

-

-

-

18,831

-

-

-

Stock-based compensation

507

2,197

3,151

2,957

2,620

4,428

3,733

2,648

4,226

4,699

5,174

Depreciation and amortization

-

46

47

28

43

102

384

750

1,040

1,573

1,785

Change in fair value of preferred stock warrants liability

1,268

-

-

-8,163

-3,081

8,804

-

-

-

-

-

Noncash lease expense

92

-

-

-

-

-

-

-

-

-

-

Directors' deferred compensation

-

166

166

132

113

125

135

169

178

187

-

Gain on sale of property and equipment

-

-

-

-

-

-

1,366

-

-

-

-

Deferred revenue amortization

-

-

-

-

-

-

-

-

8,066

51,786

11,441

Impairment of intangible assets

-

-

-

-

-

-

-

-

1,598

1,687

-

Changes in operating assets and liabilities:
Directors' deferred compensation

-

-

-

-

-

-

-

-

-

-

178

Write off of property and equipment

-

-

-

-

-

-

-

-

-

-

114

Short-term investments, trading

-

-

-

-

-

-

-

-

-

-

-2,157

Accounts receivable, net

-

-

-

-

-

-

-

-

-

277

-81

Inventory

-

-

-

-

-

-

-

-

-

55

24

Receivable from collaboration partners

-

-

-

-

-

-

-

-

-

-189

-588

Prepaid and other assets

44

572

-251

-204

1,458

577

-399

-1,857

849

-16

-85

Accounts payable

-4,762

675

1,384

838

-130

-296

-899

488

371

-420

-1,553

Accrued expenses and other liabilities

-

-3,440

1,980

950

561

-2,231

-4,246

2,885

1,707

-1,634

-

Accrued liabilities

-1,255

-

-

-

-

-

-

-

-

-

-1,956

Change in operation lease liability

-92

-

-

-

-

-

-

-

-

-

-

Deferred grant revenue

3,640

-

-

-

-

-

-

-

-

-

5,071

Net cash used in operating activities

-16,746

-39,346

-23,460

-20,778

-20,035

-28,759

-43,971

-37,109

-33,089

-30,527

-45,997

Cash flows from investing activities
Cash acquired in connection with the Merger

18,292

-

-

-

-

-

-

-

-

-

-

Acquisition related costs paid

2,155

-

-

-

-

-

-

-

-

-

-

Purchase of property and equipment

-

-

2

90

4

5

32

142

54

95

600

Proceeds from the sale of property and equipment

-

-

-

-

-

-

1,424

-

-

-

-

Purchase of short-term investments, held to maturity

-

44,155

39,283

35,404

55,219

41,905

1,425

11,980

15,145

-

-

Purchase of short-term investments, held to maturity

-

-

-

-

-

-

-

-

-

8,569

11,275

Proceeds from maturities of short-term investments, held to maturity

-

72,038

24,159

37,645

71,434

10,690

9,270

14,630

4,900

16,944

2,450

Proceeds from the sale of FARESTON, net of cash expenses

-

-

-

-

-

-

-

18,897

-

-

-

Net cash used in investing activities

16,137

27,883

-15,126

2,151

16,211

-31,220

9,237

21,405

-10,299

8,280

-9,425

Cash flows from financing activities
Net proceeds from the issuance of common stock and warrants

-

24,474

45,648

13,692

-

63,949

-

-

-

-

-

Tax payments related to shares withheld for vested restricted stock units

-

672

156

208

-

617

-

-

-

-

-

Payments on capital lease and financed equipment obligations

-

-

-

-

-

-

-

-

-

-

5

Proceeds from exercise of stock options

14

103

-

-

-

-

1,226

85

55

9

136

Proceeds from exercise of common stock warrants

1

-

-

-

-

-

-

-

-

-

-

Settlement of fractional shares upon reverse stock split

-

-

-

3

-

-

-

-

-

-

-

Payments on capital lease and financed equipment obligations

-

-

-

-

-

2

7

82

85

88

-

Proceeds from issuance of common stock

-

-

-

-

-

-

-

-

48,982

40,288

-

Net cash provided by financing activities

15

23,905

45,492

13,481

-

63,330

1,219

3

48,952

40,209

131

Net decrease in cash and cash equivalents

-594

-

-

-

-

-

-

-

-

-

-

Supplemental disclosure of non-cash investing and financing activities:
Conversion of convertible preferred stock into common stock

46,588

-

-

-

-

-

-

-

-

-

-

Issuance of 2019 bonus awards with stock options in lieu of cash

29,049

-

-

-

-

-

-

-

-

-

-

Reclassification of preferred stock warrants liability to additional paid-in capital

1,942

-

-

-

-

-

-

-

-

-

-

Net liabilities assumed in Merger

5,177

-

-

-

-

-

-

-

-

-

-

Net decrease in cash and cash equivalents

-

12,442

6,906

-5,146

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-3,824

3,351

-33,515

-15,701

5,564

17,962

-55,291

Equipment purchased under debt or capital lease

-

-

-

-

-

-

-

-

-

-

268